Inovio Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Inovio Pharmaceuticals
INO Stock  USD 1.56  0.03  1.96%   
Inovio Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Inovio Pharmaceuticals' valuation are provided below:
Gross Profit
-56.6 M
Market Capitalization
105.1 M
Enterprise Value Revenue
352.8258
Revenue
182.3 K
Earnings Share
(2.72)
We have found one hundred twenty available fundamental trends for Inovio Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Inovio Pharmaceuticals' regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 29th of January 2026, Market Cap is likely to drop to about 42.5 M. In addition to that, Enterprise Value is likely to grow to about (3.6 M)

Inovio Pharmaceuticals Total Revenue

237,898

Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 194.3 K or Total Revenue of 237.9 K, as well as many indicators such as Price To Sales Ratio of 195, Dividend Yield of 0.0053 or PTB Ratio of 0.62. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Inovio Stock
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Inovio Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets130.8 M130.2 M183.3 M
Slightly volatile
Short and Long Term Debt Total21.3 M13.6 M63.3 M
Slightly volatile
Total Current Liabilities24.1 M40.6 M34.6 M
Slightly volatile
Total Stockholder Equity94.3 M78.8 M131 M
Slightly volatile
Property Plant And Equipment Net7.7 M13.5 M12.1 M
Slightly volatile
Accounts Payable5.1 M7.4 M7.1 M
Slightly volatile
Cash79.5 M75.7 M50.2 M
Slightly volatile
Non Current Assets Total27.7 M17.7 M34.4 M
Very volatile
Cash And Short Term Investments92.3 M108.2 M133.4 M
Slightly volatile
Net Receivables1.3 M1.4 M5.3 M
Very volatile
Common Stock Shares Outstanding47.3 M31.2 M67.4 M
Pretty Stable
Liabilities And Stockholders Equity130.8 M130.2 M183.3 M
Slightly volatile
Non Current Liabilities Total12 M10.8 M17.3 M
Slightly volatile
Other Stockholder Equity2.2 B2.1 B1 B
Slightly volatile
Total Liabilities36 M51.4 M51.9 M
Slightly volatile
Property Plant And Equipment Gross34.1 M32.5 M18 M
Slightly volatile
Total Current Assets103 M112.5 M148.9 M
Slightly volatile
Intangible Assets2.3 M2.4 M4.2 M
Slightly volatile
Other Current Liabilities15.7 M30.3 M23.1 M
Slightly volatile
Other Liabilities35 K36.9 K3.3 M
Slightly volatile
Non Currrent Assets Other2.5 M2.3 M2.9 M
Pretty Stable
Common Stock Total Equity216.4 K227.8 K1.9 M
Slightly volatile
Short Term Debt2.7 M2.9 M6.8 M
Very volatile
Common Stock30.9 K32.5 K1.9 M
Slightly volatile
Property Plant Equipment5.2 M8.9 M8.2 M
Slightly volatile
Current Deferred Revenue2.1 M1.2 M2.6 M
Pretty Stable
Short Term Investments30.9 M32.5 M84.5 M
Slightly volatile
Capital Surpluse2.1 B2 B995.2 M
Slightly volatile
Long Term Investments1.4 M1.5 M7.8 M
Slightly volatile
Net Invested Capital74.8 M78.8 M164.5 M
Very volatile
Net Working Capital68.3 M71.9 M134.2 M
Pretty Stable
Capital Stock30.9 K32.5 K103.3 K
Pretty Stable
Long Term Debt Total14.2 M15 M51.9 M
Slightly volatile
Capital Lease Obligations13.6 M10.7 M19.3 M
Slightly volatile
Short and Long Term Debt13.4 M15.1 M16.5 M
Slightly volatile

Inovio Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.4 M3.6 M3.2 M
Slightly volatile
Interest Expense194.3 K204.5 K7.3 M
Pretty Stable
Total Revenue237.9 K250.4 K12.9 M
Slightly volatile
Other Operating Expenses76.2 M129.5 M111.3 M
Slightly volatile
Research Development53.3 M87 M80.2 M
Slightly volatile
Cost Of Revenue3.4 M3.6 M40.3 M
Pretty Stable
Total Operating Expenses75.9 M127.7 M111 M
Slightly volatile
Selling General Administrative44.7 B42.5 B7.3 B
Slightly volatile
Interest Income3.8 M5.5 M3.5 M
Slightly volatile
Reconciled Depreciation3.7 M2.8 M4 M
Pretty Stable
Selling And Marketing Expenses44.6 B42.5 B7.3 B
Slightly volatile

Inovio Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow32.2 M16.5 M41.3 M
Pretty Stable
Depreciation2.4 M3.6 M3.2 M
Slightly volatile
Capital Expenditures533 K561 K1.7 M
Very volatile
Total Cash From Financing Activities58.6 M59.2 M83.7 M
Pretty Stable
End Period Cash Flow79.5 M75.7 M50.2 M
Slightly volatile
Stock Based Compensation5.6 M5.9 M9.2 M
Slightly volatile
Change To Netincome20.1 M34.5 M19.7 M
Slightly volatile
Issuance Of Capital Stock30.8 M32.4 M66.4 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio195205803
Pretty Stable
Dividend Yield0.00530.0050.0052
Slightly volatile
PTB Ratio0.620.65115
Very volatile
Days Sales Outstanding1.9 K1.8 K626
Slightly volatile
Book Value Per Share3.52.93.0566
Pretty Stable
Average Payables3.7 M5 M7.8 M
Slightly volatile
Stock Based Compensation To Revenue33.0934.837.9781
Slightly volatile
Capex To Depreciation0.170.180.5922
Slightly volatile
PB Ratio0.620.65115
Very volatile
Inventory Turnover1.642.042.2016
Slightly volatile
Days Of Inventory On Hand197185166
Slightly volatile
Payables Turnover0.120.130.1465
Slightly volatile
Sales General And Administrative To Revenue16115335.3819
Slightly volatile
Average Inventory609.4 K487.5 K453.9 K
Very volatile
Research And Ddevelopement To Revenue32831376.8605
Slightly volatile
Capex To Revenue2.122.020.516
Slightly volatile
Cash Per Share2.263.123.0139
Pretty Stable
Days Payables Outstanding3.1 K2.9 K3.1 K
Slightly volatile
Income Quality0.640.870.8202
Very volatile
Intangibles To Total Assets0.03960.04170.1066
Slightly volatile
Current Ratio4.773.184.2762
Very volatile
Receivables Turnover0.20.213.85
Slightly volatile
Shareholders Equity Per Share3.472.93.0507
Pretty Stable
Debt To Equity0.150.1615.3984
Slightly volatile
Capex Per Share0.01960.02070.0483
Slightly volatile
Average Receivables12.8 M12.2 M9.5 M
Slightly volatile
Revenue Per Share0.00880.00920.5908
Slightly volatile
Interest Debt Per Share0.380.40.3892
Slightly volatile
Debt To Assets0.10.09430.408
Slightly volatile
Operating Cycle1.9 K1.8 K637
Slightly volatile
Price Book Value Ratio0.620.65115
Very volatile
Days Of Payables Outstanding3.1 K2.9 K3.1 K
Slightly volatile
Ebt Per Ebit1.241.11.1384
Very volatile
Company Equity Multiplier2.351.493.8201
Very volatile
Long Term Debt To Capitalization0.0760.080.533
Slightly volatile
Total Debt To Capitalization0.140.130.5654
Slightly volatile
Debt Equity Ratio0.150.1615.3984
Slightly volatile
Quick Ratio4.723.184.2562
Very volatile
Net Income Per E B T0.790.890.986
Slightly volatile
Cash Ratio2.452.141.74
Very volatile
Days Of Inventory Outstanding197185166
Slightly volatile
Days Of Sales Outstanding1.9 K1.8 K626
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.00471.0582
Very volatile
Price To Book Ratio0.620.65115
Very volatile
Fixed Asset Turnover0.02020.02134.3816
Slightly volatile
Debt Ratio0.10.09430.408
Slightly volatile
Price Sales Ratio195205803
Pretty Stable
Asset Turnover0.00210.00220.1184
Slightly volatile
Gross Profit Margin0.650.840.9081
Slightly volatile
Price Fair Value0.620.65115
Very volatile

Inovio Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap42.5 M44.7 M4.2 B
Pretty Stable

Inovio Fundamental Market Drivers

Inovio Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M2.1 M
Total Revenue250.4 K237.9 K
Cost Of Revenue3.6 M3.4 M
Stock Based Compensation To Revenue 34.83  33.09 
Sales General And Administrative To Revenue 152.91  160.55 
Research And Ddevelopement To Revenue 312.54  328.17 
Capex To Revenue 2.02  2.12 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(593.59)(563.91)

Pair Trading with Inovio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Inovio Stock

  0.68LIXT Lixte BiotechnologyPairCorr

Moving against Inovio Stock

  0.68CING CingulatePairCorr
  0.51ARMP Armata PharmaceuticalsPairCorr
  0.5PEPG PepGenPairCorr
  0.36PPERY Bank Mandiri Persero Earnings Call This WeekPairCorr
  0.32OABI OmniAb IncPairCorr
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
How To Invest In Inovio
Details
Is Inovio Stock a good investment?
Details
What is Inovio Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.72)
Revenue Per Share
0.005
Quarterly Revenue Growth
0.14
Return On Assets
(0.64)
Return On Equity
(3.28)
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value—what Inovio Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY